Decreased NK-cell tumour immunosurveillance consequent to JAK inhibition enhances metastasis in breast cancer models

Alessia Bottos; Dagmar Gotthardt; Jason W. Gill; Albana Gattelli; Anna Frei; Alexandar Tzankov; Veronika Sexl; Aleksandra Wodnar-Filipowicz; Nancy E. Hynes

doi:10.1038/ncomms12258

Nature Communications (Jul 2016)

Decreased NK-cell tumour immunosurveillance consequent to JAK inhibition enhances metastasis in breast cancer models

Alessia Bottos,
Dagmar Gotthardt,
Jason W. Gill,
Albana Gattelli,
Anna Frei,
Alexandar Tzankov,
Veronika Sexl,
Aleksandra Wodnar-Filipowicz,
Nancy E. Hynes

Affiliations

Alessia Bottos: Friedrich Miescher Institute for Biomedical Research
Dagmar Gotthardt: Department for Biomedical Sciences, Institute of Pharmacology and Toxicology, University of Veterinary Medicine
Jason W. Gill: Friedrich Miescher Institute for Biomedical Research
Albana Gattelli: Friedrich Miescher Institute for Biomedical Research
Anna Frei: Friedrich Miescher Institute for Biomedical Research
Alexandar Tzankov: Institute of Pathology, University Hospital Basel
Veronika Sexl: Department for Biomedical Sciences, Institute of Pharmacology and Toxicology, University of Veterinary Medicine
Aleksandra Wodnar-Filipowicz: Stem Cell Center of Competence, University of Basel
Nancy E. Hynes: Friedrich Miescher Institute for Biomedical Research

DOI: https://doi.org/10.1038/ncomms12258
Journal volume & issue: Vol. 7, no. 1
pp. 1 – 12

Abstract

Read online

JAK inhibitors are currently undergoing evaluation in clinical trials for advanced breast cancer. Here, the authors show that JAK pathway inhibition increases metastasis in mouse models of breast cancer by impairing NK anti-tumour activity and that these side effects can be overcome by addition of IL-15.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal